Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.70 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.70 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6350788 | 0.99 | KMT2A (0.77) | KMT2AMAPKAPK2MAPKAPK5S1PR1CHRM4 | |
| SCHEMBL8035748 | 0.91 | KMT2A (0.76) | KMT2AMAPKAPK2MAPKAPK5S1PR1CHRM4 | |
| SCHEMBL5541281 | 0.86 | HTR7 (0.70) | KMT2AMAPKAPK2MAPKAPK5CHRM4DRD2 | |
| SCHEMBL11277982 | 0.85 | S1PR1 (0.60) | KMT2AMAPKAPK2S1PR1HTR2BSIRT1 | |
| SCHEMBL14043228 | 0.84 | HTR7 (0.71) | KMT2AMAPKAPK2MAPKAPK5CHRM4DRD2 | |
| SCHEMBL31639048 | 0.84 | HTR7 (0.67) | KMT2AMAPKAPK2MAPKAPK5CHRM4DRD2 | |
| Bromide SCHEMBL6569631 | 0.83 | HTR7 (0.70) | KMT2AMAPKAPK2MAPKAPK5CHRM4DRD2 | |
| SCHEMBL6240399 | 0.83 | HTR7 (0.70) | KMT2AMAPKAPK2MAPKAPK5CHRM4DRD2 | |
| SCHEMBL6235224 | 0.82 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL28961219 | 0.82 | HTR2A (0.70) | MAPKAPK2S1PR1HTR2BSIRT1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | KMT2A 500/4885MAPKAPK2 1/4885MAPKAPK5 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.